SynAct Pharma – executive interview

In this interview, we speak with Jeppe Øvlesen, CEO, and Dr Thomas Jonassen, CSO of SynAct Pharma to discuss the company’s lead asset resomelagon, its unique mechanism of action and its broad applicability across inflammatory indications. Jeppe and Thomas also outline the ongoing Phase IIb trial, ADVANCE, evaluating resomelagon as a first-line treatment in rheumatoid arthritis in combination with the standard of care treatment methotrexate and SynAct’s plans for the asset. Jeppe and Thomas discuss the company’s operating performance and strong cash runway, providing headroom well past near-term catalysts, most importantly the ADVANCE trial top-line results, which are expected by end-Q126.

SynAct Pharma (STO: SYNACT) is a clinical-stage biotech company focused on the development of novel treatments to resolve, rather than inhibit, ongoing inflammatory processes in both acute and chronic diseases. Its lead asset, resomelagon (AP1189), is an oral small-molecule melanocortin 1 and 3 receptor agonist under investigation in several ongoing and planned Phase II studies in rheumatoid arthritis, virus-induced inflammation and polymyalgia rheumatica.